Daiichi Sankyo
211 Mt. Airy Road
Basking Ridge
New Jersey
07920
United States
Tel: (908) 992-6400
Website: http://www.daiichisankyo.com/
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
For more information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
460 articles with Daiichi Sankyo
-
The DESTINY-Breast04 trial introduces a new option for breast cancer diagnosis – HER2-low. The trial data received a standing ovation from thousands of oncologists at this year's ASCO meeting.
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
7/25/2022
ENHERTU ® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer.
-
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer
7/25/2022
Daiichi Sankyo and AstraZeneca have received notification of acceptance by the U.S. Food and Drug Administration of the supplemental Biologics License Application of ENHERTU® for the treatment of adult patients with unresectable or metastatic HER2 low 1+ or IHC 2+/in-situ hybridization -negative) breast cancer who have received a prior therapy in the metastatic setting.
-
Daiichi-Sankyo and AstraZeneca's sBLA for HER2 directed Enhertu accepted by FDA. Novartis gets BLA acceptance for MS biosimilar. HOOKIPA's IND for prostate cancer immunotherapy candidate accepted
-
DS-7300 Phase 2 Trial Initiated in Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
7/20/2022
Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in a global phase 2 trial evaluating the efficacy and safety of DS-7300 in patients with pretreated extensive-stage small cell lung cancer (SCLC).
-
Battle of the Patents: Daiichi Sankyo, Seagen, Alnylam, CureVac, Pfizer, BioNTech & Moderna
7/20/2022
The LPN technology used in the mRNA COVID-19 vaccines has been the target of numerous patent challenges. Here's a look at recent biopharma patent disputes. -
Research scientists have found that a colony-stimulating factor 1 receptor inhibitor may also be a potential treatment for Duchenne muscular dystrophy.
-
TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer
6/13/2022
Daiichi Sankyo (TSE: 4568) today announced that the first patient was dosed in the global TROPION-Breast02 phase 3 trial evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus investigator’s choice of chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple negative breast cancer.
-
Quizartinib Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy in Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
6/11/2022
Positive results from the global pivotal QuANTUM-First phase 3 trial of Daiichi Sankyo’s quizartinib combined with standard induction and consolidation chemotherapy and then continued as a single agent demonstrated a statistically significant and clinically meaningful improvement in overall survival in adult patients aged 18-75 with newly diagnosed FLT3-ITD positive acute myeloid leukemia compared to standard chemotherapy alone.
-
DS-6000 Suggests Early Clinical Activity in Patients with Advanced Ovarian Cancer or Renal Cell Carcinoma
6/7/2022
Daiichi Sankyo (TSE: 4568) and Sarah Cannon Research Institute (Sarah Cannon) announced that initial results from the first-in-human phase 1 study of DS-6000, a CDH6 directed DXd antibody drug conjugate (ADC), suggest early clinical activity in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.
-
Data presented at the ASCO meeting this weekend show that treatment with Enhertu demonstrated a 49% improvement in median overall survival by more than six months.
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease
6/5/2022
Detailed positive results from the pivotal DESTINY-Breast04 Phase III trial showed that ENHERTU® demonstrated superior and clinically meaningful progression-free survival and overall survival in previously treated patients with HER2-low 1+ or IHC 2+/in-situ hybridization -negative) unresectable and/or metastatic breast cancer with hormone receptor positive or HR-negative disease versus standard of care physician’s choice of chemotherapy.
-
ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease
6/5/2022
Detailed positive results from the pivotal DESTINY-Breast04 phase 3 trial showed that ENHERTU® demonstrated superior and clinically meaningful progression-free survival and overall survival in previously treated patients with HER2 low 1+ or IHC 2+/in-situ hybridization -negative) unresectable and/or metastatic breast cancer with hormone receptor positive or HR negative disease versus standard of care physician’s choice of chemotherapy.
-
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
6/3/2022
New data from Daiichi Sankyo’s (TSE: 4568) patritumab deruxtecan (HER3-DXd) showed clinically meaningful and durable responses in two early-stage trials in previously treated patients with HER3 expressing metastatic breast cancer or advanced non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
-
Daiichi Sankyo Showcases Bold Leadership in Oncology with Survival Improvements for Certain Patients with Cancer at ASCO and EHA
5/23/2022
Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio at the 2022 American Society of Clinical Oncology Scientific Program (#ASCO22) and the European Hematology Association Congress (#EHA22).
-
Celebrities' struggles with breast cancer are bringing new awareness to the importance of screening - particularly because new therapies like Radius Health's elacestrant are on the horizon.
-
On Thursday, Mersana announced that the FDA granted an orphan drug designation to one of its lead assets, XMT-2056, which is intended to treat gastric cancer.
-
AstraZeneca and Daiichi Sankyo’s breast cancer therapeutic Enhertu received supplemental approval for an earlier form of breast cancer from the U.S. Food and Drug Administration.
-
ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
5/5/2022
Daiichi Sankyo and AstraZeneca’s ENHERTU® has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
5/5/2022
ENHERTU ® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen.